In 1935, Dr Khwaja Abdul Hamied set up The Chemical, Industrial & Pharmaceutical Laboratories, which came to be popularly known as Cipla. He gave the company all his patent and proprietary formulas for several drugs and medicines, without charging any royalty. On August 17, 1935, Cipla was registered as a public limited company with an authorized capital of Rs 6 lacs. Cipla was officially opened on September 22, 1937 when the first products were ready for the market. July 4, 1939 was a red-letter day for Cipla, when the Father of the Nation, Mahatma Gandhi, honored the factory with a visit. He was “delighted to visit this Indian enterprise", he noted later. From the time Cipla came to the aid of the nation gasping for essential medicines during the Second World War, the company has been among the leaders in the pharmaceutical industry in India. Dr Yusuf Hamied, the founder's son, returned with a doctorate in chemistry from Cambridge and joined Cipla as an officer in charge of research and development in 1960. In the year of 1989 he took the command as Chairman.
Cipla is based in India’s commercial capital Mumbai, The Chemical, Industrial & Pharmaceutical Laboratories. Today, Cipla is a leading player in anti-infective and anti-asthmatic formulations. The company also specializes in the manufacturing of steroids and hormones. Cipla received clearance from the Drugs Controller General of India to manufacture and market the country's first non-nucleoside reverse transcriptase inhibitor (NNRTI), nevirapine, for the treatment of AIDS. Cipla Ltd became India’s second largest pharmaceutical, edged out the multinational giant GlaxoSmithKline which was reigning supreme in the country for long, in terms of drug sales. Cipla anticipates 15 to 20 percent growth in this year. Cipla's R&D division focuses on the development of new products and new drug delivery systems across a range of therapies. The company is spending over 4 per cent of its total turnover on R&D activities. The company supplies drugs to treat over 2 lacs HIV-positive patients worldwide. The company has also been among the major suppliers of anti-malarial drugs and drugs for schistosomiasis to international markets.
Manufacturing and R&D facilities
Cipla has 34 manufacturing facilities across India. The company has dedicated plants for the technologically-challenging formulations such as Oncology products, Hormones, Metered-Dose Inhalers (MDIs), Beta-Lactams, Cytotoxic, Injectables and Cephalosporins. Its manufacturing plants and processes are seen as among the most sophisticated in the world. They roll out world-class products in over 65 therapeutic categories.
The company use state-of-the-art technology, the most stringent operating procedures, a highly motivated and technically competent team, highest standards of safety practices and environmentally green and clean processes.
Cipla has the largest product basket among all the pharmaceutical players in India ranging from prescription to OTC to animal health, besides a big kitty for active pharmaceutical ingredients (APIs) or bulk drugs.
Amoebicides/Antiprotozoals, Anabolic steroids, Anaesthetics, Analgesics/Antipyretics, Antacids, Anthelmintics, Anti-inflammatory drugs, Anti-TB drugs, Antiacne drugs, Antiallergic drugs, Antialzheimer drugs, Antiasthma drugs, Antibiotics and Antibacterials Anticancer drugs etc.
Cipla’s over-the-counter drugs portfolio comprises the following segments Analgesics – Oral, Artificial Sweetener, Calcium Preparations, Child Care, Cold & Flu, Constipation, Cosmetics & Skin Care, Dental Care & Oral Hygiene, Diarrhoea, Food Supplements, Indigestion, Infant Food, Medicated Plasters, Medicated Shampoos, Veterinaryetc. Cipla’s animal health care products division has four sections dedicated for equine, poultry, companion animals, livestock animals products, apart from Herbal Specialities....